dainippon sumitomo pharma co
(4506:Tokyo Stock Exchange)

Executive Profile*

Background*

Mr. Mark Iwicki served as the President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. from February 19, 2010 to April 11, 2012. Mr. Iwicki served as Executive Officer of Dainippon Sumitomo Pharma Co., Ltd. until April 11, 2012. Mr. Iwicki served as the President and Chief Operating Officer of Sunovion Pharmaceuticals Inc. since February 19, 2010 and served as its Executive Vice President and Chief Commercial Officer from October 2007 to February 19, 2010. ... Mr. Iwicki joined Sunovion Pharmaceuticals Inc. from Novartis, where he served as Vice President of Cardiovascular Business Franchise Head. He led the U.S. cardiovascular franchise. Under his leadership, the cardiovascular business went from a declining market share position to regaining and sustaining market share and growth. During his career at Novartis, he held many senior positions including Vice President and Business Franchise Head, which oversaw several product franchises, including ZELNORM®, FAMVIR®, and MIACALCIN®and a portfolio of hormone replacement therapy products. He began his career at Merck & Co. Prior to his tenure with Novartis, Mr. Iwicki served in sales, marketing and management positions at Astra Merck Inc. Mr. Iwicki has been a Director of Sepracor, Inc., since February 19, 2010. He serves as a Director at Pharmaceutical Research and Manufacturers of America. He served as a Director of Sunovion Pharmaceuticals Inc. from February 19, 2010 to April 11, 2012. Mr. Iwicki earned his B.S. from Ball State University and an MBA from Loyola College.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
4506:JP	¥1,273.00 JPY	+17.00

COMPETITOR COMPENSATION